Dr. Zhi Chen is an Associate Scientific Director in the department of Sterile Product Development at Bristol Myers Squibb. He and his team are responsible for developing strategies to support formulation and process development for various drug product modalities, including proteins, oligonucleotides, AAVs, and small molecules LAIs. Dr. Chen has been a key contributor to many IND and BLA filings, playing a crucial role in advancing drug products through various stages of development. Before joining BMS, Dr. Chen's career included significant tenures at Merck, Novartis, and legacy Schering-Plough. He has been instrumental in the commercialization of several marketed products, including Keytruda®, Opdivo®, Opdualag™, and most recently, Opdivo Qvantig™.